Oct 6, 2025 04:37AM Increasing unusual option volume: OVID RVPH ARBE LAC BFLY GSM GGALA

Oct 3, 2025 01:58PM Ovid Therapeutics Inc (OVID) PT Raised to $5 at Wedbush

Oct 3, 2025 07:00AM Ovid reports positive Phase 1 results for epilepsy drug OV329

Aug 25, 2025 06:43AM H.C. Wainwright Reiterates Buy Rating on Ovid Therapeutics Inc (OVID)

Aug 13, 2025 07:01PM Ovid Therapeutics Inc. (OVID) Tops Q2 EPS by 10c

Aug 13, 2025 06:06AM Lucid Capital Markets Starts Ovid Therapeutics Inc (OVID) at Buy

Aug 8, 2025 07:51AM B.Riley Assumes Ovid Therapeutics Inc (OVID) at Buy

Jun 25, 2025 08:02AM Ovid Therapeutics (OVID) Enters Agreement with Immedica Pharma AB for Sale of Future Ganaxolone Royalties

May 27, 2025 06:38AM Ovid Therapeutics Inc (OVID) PT Lowered to $1.50 at H.C. Wainwright

May 13, 2025 05:28PM Ovid Therapeutics Inc. (OVID) Reports In-Line Q1 EPS

Mar 24, 2025 06:42AM Ovid Therapeutics Inc (OVID) PT Lowered to $2 at H.C. Wainwright

Mar 24, 2025 04:55AM Ovid Therapeutics Inc (OVID) PT Lowered to $4 at BTIG

Mar 11, 2025 04:29PM Ovid Therapeutics Inc. (OVID) Tops Q4 EPS by 4c

Mar 3, 2025 08:03AM Ovid Therapeutics (OVID) Appoints Stelios Papadopoulos to its Board

Feb 13, 2025 05:51PM Ovid Therapeutics faces Nasdaq delisting over share price

Jan 29, 2025 09:54AM Oppenheimer Upgrades Ovid Therapeutics Inc (OVID) to Outperform

Nov 12, 2024 04:45PM Ovid Therapeutics Inc. (OVID) Tops Q3 EPS by 1c

Sep 30, 2024 07:27AM H.C. Wainwright Reiterates Buy Rating on Ovid Therapeutics Inc (OVID)

Sep 27, 2024 06:28AM B.Riley Reiterates Buy Rating on Ovid Therapeutics Inc (OVID)

Sep 26, 2024 08:01AM Ovid Therapeutics (OVID) Presents Pre-Clinical Study Results Demonstrating OV329 Does Not Accumulate in Animal Eyes in Contrast with Vigabatrin

Sep 11, 2024 08:01AM Ovid Therapeutics (OVID): Meg Alexander Takes on Expanded Role as President and COO

Aug 14, 2024 06:13AM BTIG Reiterates Buy Rating on Ovid Therapeutics Inc (OVID)

Aug 13, 2024 08:13AM Ovid Therapeutics Inc. (OVID) Reports Q2 EPS of $0.12

Aug 8, 2024 08:01AM Ovid Therapeutics (OVID) Appoints Amanda Banks as Chief Development Officer

Jul 10, 2024 08:08AM Ovid Therapeutics (OVID): eNeuro Publishes Findings on the Anti-Convulsant Properties of OV329 and Its Potential Effectiveness in Treatment-Resistant Seizures

Jul 2, 2024 10:20AM TD Cowen Reiterates Buy Rating on Ovid Therapeutics Inc (OVID)

Jul 2, 2024 06:42AM H.C. Wainwright Reiterates Buy Rating on Ovid Therapeutics Inc (OVID)

Jul 1, 2024 08:02AM Ovid Therapeutics (OVID) and Graviton Bioscience Announce Topline Data from a Phase 1 Clinical Trial Studying OV888/GV101 Capsule, a Potential First-In-Class Therapy for Cerebral Cavernous Malformatio

Jun 18, 2024 09:55AM TD Cowen Reiterates Buy Rating on Ovid Therapeutics Inc (OVID)

Jun 18, 2024 06:44AM Ovid Therapeutics Inc (OVID) PT Lowered to $3 at H.C. Wainwright

Jun 18, 2024 06:32AM Oppenheimer Downgrades Ovid Therapeutics Inc (OVID) to Perform

Jun 18, 2024 04:51AM Ovid Therapeutics Inc (OVID) PT Lowered to $5 at BTIG

Jun 17, 2024 12:16PM Ovid Therapeutics Inc (OVID) PT Lowered to $1.20 at Citi

Jun 17, 2024 10:15AM Ovid Therapeutics Inc (OVID) PT Lowered to $3 at B.Riley

Jun 17, 2024 06:56AM Ovid Therapeutics (OVID) Reports on Takeda’s Announcement of Phase 3 Data for Soticlestat